<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108275</article-id><article-id pub-id-type="publisher-id">ACM-37352</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_95170384.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  抗癫痫药物与骨代谢的相关性研究的进展
  Research Progress on the Relationship between Antiepileptic Drugs and Bone Metabolism
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>安</surname><given-names>文娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>学军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院神经内科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1827</fpage><lpage>1832</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    癫痫是一种常见的慢性神经系统疾病，目前癫痫治疗仍以药物治疗为主。大多数抗癫痫药物(antiepileptic drugs, AEDs)都有不同程度的不良反应，其中一个主要的问题是AEDs对骨骼健康的影响。约50%服用AEDs的癫痫患者会出现骨骼异常，主要表现在骨代谢及骨密度方面。但早期AEDs对骨代谢的影响较容易被患者及临床医生忽视。本文主要从AEDs对骨代谢影响的早期监测、影响机制及预防治疗等方面进行阐述，为临床上AEDs药物的选择及AEDs相关骨异常患者的预防治疗提供一定的理论依据。
    Epilepsy is a common chronic nervous system disease. Epilepsy treatment is still based on drug therapy. Most antiepileptic drugs (AEDs) have different degrees of adverse reactions, and one of the main problems is the effect of AEDs on bone health. About 50% of epilepsy patients taking AEDs will have bone abnormalities, mainly in bone metabolism and bone density. However, the effect of early AEDs on bone metabolism is easy to be ignored by patients and clinicians. In this paper, the effects of AEDs on bone metabolism were mainly discussed from the aspects of early monitoring, influence mechanism and prevention and treatment, so as to provide certain theoretical basis for the selection of clinical AEDs drugs and the prevention and treatment of AEDs related bone abnormalities. 
  
 
</p></abstract><kwd-group><kwd>抗癫痫药物(AEDs)，骨代谢，骨密度，骨质疏松, Antiepileptic Drugs (AEDs)</kwd><kwd> Bone Metabolism</kwd><kwd> Bone Mineral Density</kwd><kwd> Osteoporosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>抗癫痫药物与骨代谢的相关性 研究的进展</title><p>安文娜<sup>*</sup>，高学军<sup>#</sup></p><p>延安大学附属医院神经内科，陕西 延安</p><disp-formula id="hanspub.37352-formula107"><graphic xlink:href="//html.hanspub.org/file/46-1571527x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年8月3日；录用日期：2020年8月21日；发布日期：2020年8月28日</p><disp-formula id="hanspub.37352-formula108"><graphic xlink:href="//html.hanspub.org/file/46-1571527x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>癫痫是一种常见的慢性神经系统疾病，目前癫痫治疗仍以药物治疗为主。大多数抗癫痫药物(antiepileptic drugs, AEDs)都有不同程度的不良反应，其中一个主要的问题是AEDs对骨骼健康的影响。约50%服用AEDs的癫痫患者会出现骨骼异常，主要表现在骨代谢及骨密度方面。但早期AEDs对骨代谢的影响较容易被患者及临床医生忽视。本文主要从AEDs对骨代谢影响的早期监测、影响机制及预防治疗等方面进行阐述，为临床上AEDs药物的选择及AEDs相关骨异常患者的预防治疗提供一定的理论依据。</p><p>关键词 :抗癫痫药物(AEDs)，骨代谢，骨密度，骨质疏松</p><disp-formula id="hanspub.37352-formula109"><graphic xlink:href="//html.hanspub.org/file/46-1571527x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/46-1571527x8_hanspub.png" /> <img src="//html.hanspub.org/file/46-1571527x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 导言</title><p>癫痫是影响全球约6500万人的最常见的反复发作的神经疾病 [<xref ref-type="bibr" rid="hanspub.37352-ref1">1</xref>]，其中约1000万生活在中国。根据最近的流行病学调查，在中国，癫痫的发病率约在4%到7%之间 [<xref ref-type="bibr" rid="hanspub.37352-ref2">2</xref>]。目前，癫痫的治疗主要以药物治疗为主，大部分癫痫患者经过合理、正规的抗癫痫药物(AEDs)治疗即可控制其发作。癫痫的药物治疗往往是长期甚至是终生的治疗过程，所以癫痫患者在选用AEDs治疗时，必须考虑药物间相互作用和潜在的副作用。有关癫痫的横断面和前瞻性研究表明，长期服用AEDs与各种代谢、内分泌和激素紊乱之间存在共同的联系，即使在AEDs的治疗范围内也可能出现这些障碍 [<xref ref-type="bibr" rid="hanspub.37352-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.37352-ref4">4</xref>]。其中AEDs对骨骼的代谢影响在临床上较易被忽视，其原因是AEDs所致的大多数骨效应长期处于亚临床状态，临床表现可能需要数年时间。有研究表明，在服用AEDs治疗的癫痫患者中，一半以上患者存在骨骼异常 [<xref ref-type="bibr" rid="hanspub.37352-ref5">5</xref>]。而AEDs也是一种多功能药物，广泛应用于慢性疼痛、躁郁症、偏头痛和其它神经或精神疾病，而且通常为长期治疗。所以，了解与AEDs使用相关的骨代谢紊乱是非常重要的。</p></sec><sec id="s4"><title>2. 骨异常的检测</title><sec id="s4_1"><title>2.1. 双能X线吸收测定法(Dual-Energy X-Ray Absorptiometry, DXA)</title><p>通过双能X射线吸收仪测量的骨密度值取决于骨矿物质含量(bone mineral content, BMC)和骨大小。典型的DXA扫描包括脊柱、髋部和腕部的选定区域，因为这些区域是骨质疏松性骨折最先和最常受影响的区域。常规的X射线可以识别骨折，但如果骨密度(bone mineral density, BMD)降低小于30%时，则不能检测到这些骨疾病 [<xref ref-type="bibr" rid="hanspub.37352-ref6">6</xref>]。</p></sec><sec id="s4_2"><title>2.2. 骨代谢与骨转换标志物</title><p>骨和矿物质代谢的生化指标包括血清钙、血清磷、25-羟基维生素D(25(OH)D3)、甲状旁腺激素(parathyroid hormone, PTH)和骨重塑标记物的血浓度测量等。而骨转换标记物(Bone turnover makers, BTMs)是在骨形成和吸收过程中释放的酶和蛋白质，骨代谢的生化监测可以通过测定血清及尿液中骨代谢标志物的水平来进行评估。</p><p>骨形成标志物包括I型前胶原氨基末端肽(N-terminal propeptide of type I procollagen, PINP)、血清骨碱性磷酸酶(serum bone alkaline phosphatase, BALP)、I型前胶原C端前肽(carboxy-terminal propeptide of type 1 procollagen, PICP)和骨钙素(osteocalcin, OC)等。骨吸收标志物主要包括尿中I型胶原C端交联肽(urinary excretion of C-, CTX)、I型胶原N端交联肽(urinary excretion of N-, NTX)和β-胶原特殊系列等(β-Crosslaps, β-CTX)。骨转换标志物作为一种辅助手段，可以在一个时间点测量骨转换率以及骨形成和吸收之间的平衡。这些标志物有助于预测未来低骨密度或骨折风险并监测患者，记录骨质疏松症预防或治疗策略的需要 [<xref ref-type="bibr" rid="hanspub.37352-ref7">7</xref>]。</p></sec></sec><sec id="s5"><title>3. AEDs对骨代谢的影响</title><p>一项包含71名癫痫患者的横断面研究示：在受试者中，酶诱导药物如苯妥英钠(phenytoin, PHT)、苯巴比妥(phenobarbital, PB)、卡马西平(carbamazepine, CBZ)和扑米酮的骨密度低于非酶诱导药物如丙戊酸钠(valproate, VPA)、拉莫三嗪(lamotrigine, LTG)、氯硝西泮、加巴喷丁(gabapentin, GBP)、托帕胺酸和乙氧嘧啶的骨密度 [<xref ref-type="bibr" rid="hanspub.37352-ref8">8</xref>]。最近一项关于VPA对骨密度及骨代谢影响的荟萃分析显示：VPA可降低癫痫患者的腰椎和股骨颈BMD，提高血清B-ALP水平。VPA治疗癫痫患儿血清PTH水平升高，血清25(OH)D3降低，而在成年人中这些指标没有改变 [<xref ref-type="bibr" rid="hanspub.37352-ref9">9</xref>]。</p><p>随着对癫痫发生发展机制研究深入，以及传统药物升级，许多新型抗癫痫药物(AEDs)不断面市。这些新的AEDs有望改善生活质量，减少对许多癫痫患者的不利影响。但仍存在一些问题：这些新的AEDs，如LTG、GBP、奥卡西平(oxcarbazepine, OXC)、左乙拉西坦(levetiracetam, LEV)和托吡酯(Topiramate, TPM)是否会引起骨骼变化。文献检索显示，关于新型AEDs对骨健康影响的研究有限，而且结果相互矛盾。</p><p>有一项对41例服用OXC单药治疗的癫痫患者进行了骨代谢生化标志物(血清钙、BALP、PTH、25(OH)D3水平等)和骨密度的研究，其中大多数标记物没有改变，仅有血清钙和BALP水平降低，在部分女性患者中，发现其腰椎(L2-L4)测得的骨密度甚至增加 [<xref ref-type="bibr" rid="hanspub.37352-ref10">10</xref>]。一项试验研究了单用OXC治疗(18个月)对青春期前和青春期儿童骨转换的影响，作者注意到尽管服用OXC治疗的患者的骨代谢指标(如骨钙素)的变化有统计学意义，但对于骨密度正常的儿童，其发生的影响似乎微不足道 [<xref ref-type="bibr" rid="hanspub.37352-ref11">11</xref>]。早前一些研究显示LTG对骨代谢及骨密度几乎没有影响。一项针对雌性大鼠的实验中获得的实验数据显示，低剂量的LEV导致股骨颈(主要是小梁骨)生物力学强度下降，骨钙素水平下降 [<xref ref-type="bibr" rid="hanspub.37352-ref12">12</xref>]。然而，在对新接受LEV治疗的患者进行的1年前瞻性临床研究中，没有发现骨密度显著下降，这意味着LEV也可能不会对骨强度和代谢产生负面影响 [<xref ref-type="bibr" rid="hanspub.37352-ref13">13</xref>]。这些结果得到了Fekete等人的支持 [<xref ref-type="bibr" rid="hanspub.37352-ref14">14</xref>]。张等人证明托吡酯(TPM)降低了儿童骨密度，并观察了血清钙、磷含量的变化 [<xref ref-type="bibr" rid="hanspub.37352-ref15">15</xref>]。较早的一些研究数据表明，TPM没有显著改变骨钙素或CTX的水平。但Heo等人的研究显示长期服用TPM可能对骨骼有负面影响。他们的数据表明，TPM或CBZ治疗组的血清钙浓度显著低于VPA组(p &lt; 0.001)。更重要的是，TPM治疗组患者的其它生物标志物也发生了改变：与对照组相比，PTH水平降低(p &lt; 0.001)，BALP (p &lt; 0.001)和骨钙素(p = 0.005)水平升高 [<xref ref-type="bibr" rid="hanspub.37352-ref16">16</xref>]。目前，针对新型AEDs药物对骨代谢的影响尚未有统一定论。这说明，有关较新的AEDs对骨健康影响的进一步数据是必需的。</p></sec><sec id="s6"><title>4. AEDs对骨代谢影响的机制</title><p>AEDs诱发的骨疾病的潜在的病理生理机制尚不明确，但单一的机制并不能完全解释所有AEDs对骨健康的影响，所以，就目前来说，多种机制已经被提出。</p><sec id="s6_1"><title>4.1. 维生素D缺乏、低钙血症与降钙素紊乱</title><p>酶诱导AEDs (enzymes induce antiepileptic drugs, EIAEDs)诱导肝脏细胞色素P450系统，使维生素D及其代谢物的周转加速。这会导致维生素D不足，肠道钙吸收减少，血清钙降低，继而发生甲状旁腺功能亢进，骨密度降低，最终导致骨折增加。有关研究指出AEDs所致的降钙素分泌紊乱，会抑制骨吸收方面发挥生理作用 [<xref ref-type="bibr" rid="hanspub.37352-ref17">17</xref>]。VPA可导致肾小管功能障碍，间接增加尿钙和磷的流失。有人认为TPM和唑尼酰胺可能会引起继发性骨异常，两者都是碳酸酐酶抑制剂，可导致肾酸中毒、低血钙、低磷血症和继发性骨异常 [<xref ref-type="bibr" rid="hanspub.37352-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37352-ref15">15</xref>]。</p></sec><sec id="s6_2"><title>4.2. 直接加速骨丢失与骨生长不良</title><p>有研究显示，AEDs会直接影响生长板软骨细胞或骨增殖，进而引起骨生长不良和骨丢失 [<xref ref-type="bibr" rid="hanspub.37352-ref18">18</xref>]。Lee等人报道了VPA治疗会直接影响生长板软骨细胞增殖 [<xref ref-type="bibr" rid="hanspub.37352-ref19">19</xref>]。这些影响主要表现在AEDs对骨代谢标志物(BTMs)的改变。</p></sec><sec id="s6_3"><title>4.3. 内分泌紊乱</title><p>众所周知，EIAEDs对男性和女性的内分泌都会有一定的不良影响。AEDs可能增强性类固醇的新陈代谢，导致生物可利用的内源性雌二醇和睾酮水平下降，这两者在骨健康中起着重要的作用，其水平的下降会导致骨质流失。因此，骨丢失速率的增加可能是这种类固醇代谢增加的结果。绝经后雌激素水平的下降加速了骨丢失，可能使绝经后妇女成为AEDs诱导的骨丢失的更易受攻击的靶点。除此之外，在女性患者中，VPA会导致雄激素升高、血清睾酮浓度升高、月经紊乱和多囊卵巢 [<xref ref-type="bibr" rid="hanspub.37352-ref20">20</xref>]。</p></sec><sec id="s6_4"><title>4.4. 高同型半胱氨酸血症、叶酸及维生素K的缺乏</title><p>研究表明，服用AEDs会导致血清总同型半胱氨酸水平的升高 [<xref ref-type="bibr" rid="hanspub.37352-ref21">21</xref>]，而同型半胱氨酸会增加破骨细胞活性，降低成骨细胞活性，减少骨组织的血液流动，通过直接与基质胶原结合并通过金属蛋白酶降解基质，最终显著降低骨骼强度。此外，研究还发现，过量的同型半胱氨酸减少了骨小梁的数量 [<xref ref-type="bibr" rid="hanspub.37352-ref22">22</xref>]。有人认为叶酸可以保持骨细胞中一氧化氮合酶的活性，从而刺激成骨细胞的活性，同时抑制骨分解代谢。另一种理论是基于维生素K和EIAEDs之间的相互作用。已经证明，这些药物降低了血清中维生素K的水平，而维生素K是成骨细胞合成的Gla蛋白羧化的主要辅助因子，其中以骨钙素最为丰富。骨钙素羧化作用的降低会促使骨密度降低，从而增加病理性骨折的风险 [<xref ref-type="bibr" rid="hanspub.37352-ref23">23</xref>]。</p></sec><sec id="s6_5"><title>4.5. 其他机制</title><p>肉碱可能是AEDs引起骨丢失增加的另一个原因。左旋肉碱对成骨细胞的能量补充至关重要，肉碱缺乏会导致成骨细胞功能障碍和骨保护蛋白形成缺陷。据报道，瘦素对骨代谢有一定的影响。瘦素在可通过下丘脑受体间接影响成骨细胞的活性，减少成骨细胞的数量 [<xref ref-type="bibr" rid="hanspub.37352-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.37352-ref25">25</xref>]。研究发现，服用两种及以下AEDs治疗的患者中，有7%~46%会出现低钠血症 [<xref ref-type="bibr" rid="hanspub.37352-ref26">26</xref>]。这是与CBZ和奥卡西平(OXC)等EIAED治疗相关的常见不良反应。除此之外，服用VPA与LEV的患者也会出现慢性低钠血症。许多研究已经证实了低钠血症与骨质疏松和骨折之间存在着密切的关系 [<xref ref-type="bibr" rid="hanspub.37352-ref27">27</xref>]。最近的一项研究证明：在排除癫痫患者骨质疏松的已知危险因素后，证实中度和重度低钠血症是腰椎骨密度降低的独立危险因素 [<xref ref-type="bibr" rid="hanspub.37352-ref28">28</xref>]。</p></sec></sec><sec id="s7"><title>5. 预防及治疗</title><p>许多治疗方案可用于预防和治疗骨密度降低，包括钙剂、维生素D的补充、双膦酸盐及激素替代疗法等。但是目前还没有关于预防、减少或治疗癫痫相关或AEDs相关骨病的官方共识指南。目前有证据表明，许多由AEDs治疗引起的骨病可以通过给予钙和维生素D (胆钙化醇或麦角钙化醇)来治疗或预防 。但由于AEDs治疗的个体中没有关于钙和维生素D治疗的官方建议，所以谨慎的做法是现在按照医学研究所发布的建议，在普通人群中每日摄入钙和维生素D。研究人员认为，血清25(OH)D水平 ≥ 30 ng/ml可能是获得最佳健康效益所必需的 [<xref ref-type="bibr" rid="hanspub.37352-ref29">29</xref>]。医学、食品和营养研究所委员会建议避免使用高剂量，因为过量的维生素D及钙可能会导致肝、肾功能不全，最终反而会使骨量降低。双膦酸盐是抗骨吸收的化合物，广泛用于治疗骨丢失相关疾病。双膦酸盐通过抑制破骨细胞活性、增加骨密度和减少椎体骨折来减缓骨丢失。然而，一般来说，由于双膦酸盐具有致畸潜能，因此通常不推荐用于绝经前妇女，而且其在儿童中的应用也需慎重。改变生活方式等非药理学措施对改善AEDs患者的骨骼健康具有重要作用。应强调有规律的体育活动、均衡的饮食和充足的蛋白质摄入、戒烟和过量饮酒。</p></sec><sec id="s8"><title>6. 结论及展望</title><p>综上所述，目前大量的研究已经表明，由AEDs药物诱导的骨病具有不同的严重程度：轻者无症状，但其骨代谢相关生化标志物已发生改变；较严重的患者会发生骨质疏松甚至骨折；最终会有较少一部分可能会发展为佝偻病或骨软化症。因此，对服用AEDs治疗的患者建议进行早期的骨代谢检测及定期的骨健康筛查。尽管目前对AEDs诱导骨转换增强的潜在机制的理解已有进展，但确切的机制仍不清楚。因此，了解不同类型AEDs (新、旧AEDs)对骨和矿物质代谢紊乱的病理生理学有助于识别和监测高危患者，并制定适当的预防和治疗措施。另一方面，应当对AEDs所致骨异常的预防及治疗药物(如钙和维生素D)进行更多的随机对照试验，为这些药物的使用剂量、时机提供更多的临床依据。</p></sec><sec id="s9"><title>文章引用</title><p>安文娜,高学军. 抗癫痫药物与骨代谢的相关性研究的进展Research Progress on the Relationship between Antiepileptic Drugs and Bone Metabolism[J]. 临床医学进展, 2020, 10(08): 1827-1832. https://doi.org/10.12677/ACM.2020.108275</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37352-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moshé, S.L., Perucca, E., Ryvlin, P. and Tomson, T. (2015) Epilepsy: New Advances. The Lancet, 385, 884-898.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(14)60456-6</mixed-citation></ref><ref id="hanspub.37352-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Naylor, J., Thevathasan, A., Churilov, L., et al. (2018) Association between Different Acute Stroke Therapies and Development of Post Stroke Seizures. BMC Neurology, 18, Article No. 61.  
&lt;br&gt;https://doi.org/10.1186/s12883-018-1064-x</mixed-citation></ref><ref id="hanspub.37352-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hamed, S.A., Radwan, M.E.N., Haridi, M.A., et al. (2014) Thyroid Gland Volume in Adults with Epilepsy: Relationship to Thyroid Hormonal Function. Neurology and Neuroscience, 5, 2.</mixed-citation></ref><ref id="hanspub.37352-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hamed, S.A., et al. (2015) Evaluation of Penile Vascular Status in Men with Epilepsy with Erectile Dysfunction. Seizure, 25, 40-48. &lt;br&gt;https://doi.org/10.1016/j.seizure.2014.12.002</mixed-citation></ref><ref id="hanspub.37352-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lazzari, A.A., Dussault, P.M., Thakore-James, M., et al. (2013) Prevention of Bone Loss and Vertebral Fractures in Patients with Chronic Epilepsy—Antiepileptic Drug and Osteoporosis Prevention Trial. Epilepsia, 54, 1997-2004.  
&lt;br&gt;https://doi.org/10.1111/epi.12351</mixed-citation></ref><ref id="hanspub.37352-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Abeş, M., Sarihan, H. and Madenci, E. (2003) Evaluation of Bone Mineral Density with Dual X-Ray Absorptiometry for Osteoporosis in Children with Bladder Augmentation. Journal of Pediatric Surgery, 38, 230-232.  
&lt;br&gt;https://doi.org/10.1053/jpsu.2003.50050</mixed-citation></ref><ref id="hanspub.37352-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Eastell, R. and Hannon, R.A. (2008) Biomarkers of Bone Health and Osteoporosis Risk: Symposium on “Diet and Bone Health”. Proceedings of the Nutrition Society, 67, 157-162. &lt;br&gt;https://doi.org/10.1017/S002966510800699X</mixed-citation></ref><ref id="hanspub.37352-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shen, C., Chen, F., Zhang, Y., Guo, Y. and Ding, M. (2014) Association between Use of Antiepileptic Drugs and Fracture Risk: A Systematic Review and Meta-Analysis. Bone, 64, 246-253.  
&lt;br&gt;https://doi.org/10.1016/j.bone.2014.04.018</mixed-citation></ref><ref id="hanspub.37352-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fan, D., Miao, J., Fan, X., Wang, Q. and Sun, M. (2019) Effects of Valproic Acid on Bone Mineral Density and Bone Metabolism: A Meta-Analysis. Seizure, 73, 56-63. &lt;br&gt;https://doi.org/10.1016/j.seizure.2019.10.017</mixed-citation></ref><ref id="hanspub.37352-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Koo, D.L., Hwang, K.J., Han, S.W., et al. (2014) Effect of Oxcarbazepine on Bone Mineral Density and Biochemical Markers of Bone Metabolism in Patients with Epilepsy. Epilepsy Research, 108, 442-447.  
&lt;br&gt;https://doi.org/10.1016/j.eplepsyres.2013.09.009</mixed-citation></ref><ref id="hanspub.37352-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cansu, A., Yesilkaya, E., Serdaroğlu, A., et al. (2008) Evaluation of Bone Turnover in Epileptic Children Using Oxcarbazepine. Pediatric Neurology, 39, 266-271. &lt;br&gt;https://doi.org/10.1016/j.pediatrneurol.2008.07.001</mixed-citation></ref><ref id="hanspub.37352-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Nissen-Meyer, L.S., Svalheim, S., Taubøll, E., et al. (2007) Levetiracetam, Phenytoin, and Valproate Act Differently on Rat Bone Mass, Structure, and Metabolism. Epilepsia, 48, 1850-1860.  
&lt;br&gt;https://doi.org/10.1111/j.1528-1167.2007.01176.x</mixed-citation></ref><ref id="hanspub.37352-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Koo, D.L., Joo, E.Y., Kim, D. and Hong, S.B. (2013) Effects of Levetiracetam as a Monotherapy on Bone Mineral Density and Biochemical Markers of Bone Metabolism in Patients with Epilepsy. Epilepsy Research, 104, 134-139.  
&lt;br&gt;https://doi.org/10.1016/j.eplepsyres.2012.09.002</mixed-citation></ref><ref id="hanspub.37352-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fekete, S., Simko, J., Gradosova, I., et al. (2013) Erratum to “The Effect of Levetiracetam on Rat Bone Mass, Structure and Metabolism” [Epilepsy Res. 107 (2013) 56-60]. Epilepsy Research, 107, 56-60.  
&lt;br&gt;https://doi.org/10.1016/j.eplepsyres.2013.11.015</mixed-citation></ref><ref id="hanspub.37352-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张静, 王凯旋, 韦翊, 等. 托吡酯和卡马西平对癫痫患儿骨代谢的影响[J]. 中国当代儿科杂志, 2010, 12(2): 96-98.</mixed-citation></ref><ref id="hanspub.37352-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Heo, K., Rhee, Y., Lee, H.W., et al. (2011) The Effect of Topiramate Monotherapy on Bone Mineral Density and Markers of Bone and Mineral Metabolism in Premenopausal Women with Epilepsy. Epilepsia, 52, 1884-1889.  
&lt;br&gt;https://doi.org/10.1111/j.1528-1167.2011.03131.x</mixed-citation></ref><ref id="hanspub.37352-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Arora, E., Singh, H. and Gupta, Y.K. (2016) Impact of Antiepileptic Drugs on Bone Health: Need for Monitoring, Treatment, and Prevention Strategies. Journal of Family Medicine and Primary Care, 5, 248-253.  
&lt;br&gt;https://doi.org/10.4103/2249-4863.192338</mixed-citation></ref><ref id="hanspub.37352-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mikati, M.A., Dib, L., Yamout, B., Sawaya, R., Rahi, A.C. and Fuleihan, G.-H. (2006) Two Randomized Vitamin D Trials in Ambulatory Patients on Anticonvulsants: Impact on Bone. Neurology, 67, 2005-2014. 
&lt;br&gt;https://doi.org/10.1212/01.wnl.0000247107.54562.0e</mixed-citation></ref><ref id="hanspub.37352-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lee, H.S., Wang, S.Y., Salter, D.M., Wang, C.C., Chen, S.J. and Fan, H.C. (2013) The Impact of the Use of Antiepileptic Drugs on the Growth of Children. BMC Pediatrics, 13, Article No. 211.  
&lt;br&gt;https://doi.org/10.1186/1471-2431-13-211</mixed-citation></ref><ref id="hanspub.37352-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Svalheim, S., Sveberg, L., Mochol, M. and Taubøll, E. (2015) Interactions between Antiepileptic Drugs and Hormones. Seizure, 28, 12-17. &lt;br&gt;https://doi.org/10.1016/j.seizure.2015.02.022</mixed-citation></ref><ref id="hanspub.37352-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D.W., Lee, S.Y., Shon, Y.M. and Kim, J.H. (2013) Effects of New Antiepileptic Drugs on Circulatory Markers for Vascular Risk in Patients with Newly Diagnosed Epilepsy. Epilepsia, 54, e146-e149.  
&lt;br&gt;https://doi.org/10.1111/epi.12338</mixed-citation></ref><ref id="hanspub.37352-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Behera, J., Bala, J., Nuru, M., Tyagi, S.C. and Tyagi, N. (2017) Homocysteine as a Pathological Biomarker for Bone Disease. Journal of Cellular Physiology, 232, 2704-2709. &lt;br&gt;https://doi.org/10.1002/jcp.25693</mixed-citation></ref><ref id="hanspub.37352-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yazdanpanah, N., Zillikens, M.C., Rivadeneira, F., et al. (2007) Effect of Dietary B Vitamins on BMD and Risk of Fracture in Elderly Men and Women: The Rotterdam Study. Bone, 41, 987-994.  
&lt;br&gt;https://doi.org/10.1016/j.bone.2007.08.021</mixed-citation></ref><ref id="hanspub.37352-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Karsenty, G. (2006) Convergence between Bone and Energy Homeostases: Leptin Regulation of Bone Mass. Cell Metabolism, 4, 341-348. &lt;br&gt;https://doi.org/10.1016/j.cmet.2006.10.008</mixed-citation></ref><ref id="hanspub.37352-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Takeda, S. and Karsenty, G. (2008) Molecular Bases of the Sympathetic Regulation of Bone Mass. Bone, 42, 837-840. 
 &lt;br&gt;https://doi.org/10.1016/j.bone.2008.01.005</mixed-citation></ref><ref id="hanspub.37352-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Berghuis, B., Van Der Palen, J., DE Haan, G.J., et al. (2017) Carbamazepine- and Oxcarbazepine-Induced Hyponatremia in People with Epilepsy. Epilepsia, 58, 1227-1233. &lt;br&gt;https://doi.org/10.1111/epi.13777</mixed-citation></ref><ref id="hanspub.37352-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kinsella, S., Moran, S., Sullivan, M.O., Molloy, M.G. and Eustace, J.A. (2010) Hyponatremia independent of Osteoporosis Is Associated with Fracture Occurrence. Clinical Journal of the American Society of Nephrology, 5, 275-280.  
&lt;br&gt;https://doi.org/10.2215/CJN.06120809</mixed-citation></ref><ref id="hanspub.37352-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Diemar, S.S., Sejling, A.S., Eiken, P., Suetta, C., Jørgensen, N.R. and Andersen, N.B. (2019) Hyponatremia and Metabolic Bone Disease in Patients with Epilepsy: A Cross-Sectional Study. Bone, 123, 67-75. 
&lt;br&gt;https://doi.org/10.1016/j.bone.2019.03.017</mixed-citation></ref><ref id="hanspub.37352-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Erbayat Altay, E., Serdaroğlu, A., Tümer, L., Gücüyener, K. And Hasanoğlu, A. (2000) Evaluation of Bone Mineral Metabolism in Children Receiving Carbamazepine and Valproic Acid. Journal of Pediatric Endocrinology and Metabolism, 13, 933-939. &lt;br&gt;https://doi.org/10.1515/JPEM.2000.13.7.933</mixed-citation></ref></ref-list></back></article>